Response times follow lognormal or gamma distribution in arthritis patients

Journal of Clinical Epidemiology

Volumn 63, Issue 12, 2010, Pages 1363-1369

  Abrahamyan, Lusine ^a,b   Beyene, Joseph ^a,b   Feng, Jingyuan ^c   Chon, Yun ^c   Willan, Andrew R ^a,b   Schmeling, Heinrike ^d   Horneff, Gerd ^e   Keystone, Edward C ^f   Feldman, Brian M ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c AMGEN INC   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e Asklepios Clinic   (Germany)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Clinical Trials; Etanercept; Juvenile idiopathic arthritis; Methotrexate; Rheumatoid arthritis; Survival distribution

Indexed keywords

CORTICOSTEROID; ETANERCEPT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE DURATION; DISEASE REGISTRY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NORMAL DISTRIBUTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SECONDARY ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; GERMANY; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 78049257771     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2009.11.019     Document Type: Article

References (13)

1. E.T. Lee, and J.W. Wang Statistical methods for survival data analysis 3rd ed 2003 John Wiley & Sons, Inc New York
2. W.D. Dupont, and W.D. Plummer Jr. Power and sample size calculations. A review and computer program Control Clin Trials 11 2 1990 116 128
3. J.M. Lachin, and M.A. Foulkes Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification Biometrics 42 3 1986 507 519
4. T. Doan, and E. Massarotti Rheumatoid arthritis: an overview of new and emerging therapies J Clin Pharmacol 45 2005 751 762
5. L. Klareskog, D. van der Heijde, J.P. de Jager, A. Gough, J. Kalden, and M. Malaise Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Lancet 363 2004 675 681
6. G. Horneff, H. Schmeling, T. Biedermann, I. Foeldvari, G. Ganser, and H.J. Girschick The German etanercept registry for treatment of juvenile idiopathic arthritis Ann Rheum Dis 63 2004 1638 1644
7. G. Horneff, F. De Bock, I. Foeldvari, H.J. Girschick, H. Michels, and D. Moebius Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry Ann Rheum Dis 68 4 2009 519 525
8. D.T. Felson, J.J. Anderson, M. Boers, C. Bombardier, M. Chernoff, and B. Fried The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials Arthritis Rheum 36 1993 729 740
9. E.H. Giannini, N. Ruperto, A. Ravelli, D.J. Lovell, D.T. Felson, and A. Martini Preliminary definition of improvement in juvenile arthritis Arthritis Rheum 40 1997 1202 1209
10. J.C. Lindsey, and L.M. Ryan Tutorial in biostatistics methods for interval-censored data Stat Med 17 2 1998 219 238
11. K.P. Burnham, and D.R. Anderson Multimodel inference. Understanding AIC and BIC in model selection Sociol Methods Res 33 2 2004 261 304
12. K.P. Burnham, and D.R. Anderson Model selection and multimodel inference: a practical information-theoretic approach 2nd ed 2002 Springer-Verlag New York, NY
13. U.S. Food and Drug Administration Challenge and opportunity on the critical path to new medical products Available at http://www.fda.gov/ ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/ucm077262.htm 2004 Accessed Jan 21, 2009